Drug
discovery is used for the identification of the lead structure, which is
followed by the synthesis of its analogs, and the latter’s screening to get
candidate molecules for drug development. The objective of the drug discovery
process is to search for new drug molecules that can bind to a specific target.
Further, in the traditional drug discovery process, identifying the suitable
drug target is the first and foremost task.
The
different steps associated with the in-silico drug discovery process include
target identification, target validation, lead identification, lead
optimization, pre-clinical studies, and clinical trials. The market for
in-silico drug discovery is focused on software, services, and artificial
intelligence. Advanced software and informatics deliver far more insight than
traditional methods, with a resolution significantly higher than ever before.
According
to the market study published by BIS Research, the in-silico
drug discovery market was estimated at $2,094.5 million in 2018 and is
expected to grow at a CAGR of 12.92% during the forecast period 2019-2029.
The
global in-silico drug discovery market was segmented on the basis of end-users,
including contract research organizations (CRO), pharmaceutical industry,
academic and research institutes, and other end users (hospitals and other care
facilities).
Recently,
in-silico drug discovery has gained a lot of popularity. The major reason for
drug discovery’s popularity is the analysis of data generated from different
technologies such as next-generation sequencing and non-invasive or minimally
invasive diagnostic technologies. Due to the application of informatics, tools
such as data semantics and visual analytics are being used in the industry. The
usage of these tools has increased research effectiveness, improved
predictability, and fostered effective teamwork among scientists. The
pharmaceutical industry contributed the maximum share in 2018 and is expected
to dominate the market share in the future as well.
In
addition, as per the regional data of the in-silico drug discovery market,
North America contributed the maximum to the market. However, it is the region
of Asia-Pacific that is expected to grow with the highest CAGR during the
forecast period from 2019 to 2029.
Comments
Post a Comment